ABSTRACT
Background: Evolution of individualized radiosurgical therapeutic methods for brain metastasis as an ominous prognostic finding may encourage a more extensive application of neuroimaging in patients with extracerebral cancer. The aim of the present study was to investigate the added value of brain-included 18 F FDG PET/CT acquisition protocol based on primary cancer type and clinical indication
Materials and Methods: A retrospective review was performed on 3945 18 F FDG PET/CT reports of patients with extra-cerebral cancer underwent brain-included PET/CT study. Cerebral lesions suggestive of brain metastasis were subsequently verified by MRI, MRI+MRS, surgical pathology and a 1-year clinical formal follow up. The detection rate of new brain metastasis and related impact on disease status were then investigated in each cancer type based on clinical indication
Results: Of a total 3933 eligible patients, 44 [1.12%] were finally verified to have new cerebral metastasis. The most common primary sources were lung cancer [19/385, 4.93%], cancer of unknown primary [CUP] [5/168, 2.97%] and breast cancer [8/468, 1.71%]. The most common clinical indications were initial staging [17/44, 43.1%] and restaging [19/44, 36.4%]. Change in disease status occurred in 12 out of 44 patients [27.3%], more frequently occurred in lung cancer [n=4], in all indications and breast [n=3] cancers at restaging [n=7, 43.8%]
Conclusion: PET/CT acquisition protocol study may be best optimized based on the type of primary cancer and timing of evaluation. Brain-included field of view may be recommended for lung cancer regardless the clinical indication, cancer of unknown primary and breast cancer at restaging
ABSTRACT
Given the unmet needs in cancer treatment, extensive research and development has evolved to offer therapies for cancers to extend survival and minimize side effects. Immunotherapy, an approach to harness normal immune cells against cancers not only today's breakthrough but in fact the future of oncology therapeutics. Taking into consideration the recent approvals for new lines of therapy including anti-programmed-death-1 or programmed-death-1 ligand [PD-1/PD-L1] monoclonal antibodies for the treatment of Malignant Melanoma [MM] and Non-Small Cell Lung Cancer [NSCLC], local strategies need to be established following the field experts' concurrence. Expert input forums are among the key approaches to define locally-adapted clinical-pathways with regard to the novel treatments. To this end, a panel of Iranian medical oncology experts reviewed the available evidence, taking into consideration recent practice guidelines with regard to the treatment of MM and NSCLC in order to draw an agreed-upon approach highlighting the position of immunotherapy in their current practice. Having addressed the key questions and considering the possible limitations and challenges, the panel could reach an agreed position. This report highlights the discussions with regards to the role of immunotherapy in MM and NSCLC during the immune-oncology clinical forum [IOCF] comprising an Iranian panel of experts
ABSTRACT
Human papilloma virus causes benign and malignant abnormalities in different part of the body. The link between high risk types of HPV and some anogenital and aerodigestive tract cancer is well established. Oral HPV infection plays a role in developing oropharyngeal squamous cell carcinoma. We studied the prevalence of oral HPV in healthy individuals and its relative risk factors. Saliva samples of 114 healthy subjects were collected for HPV DNA analysis. Volunteers completed questionnaires and signed a written consent. For data analysis descriptive statistic, chi square test and odds ratio was used. The frequency of oral HPV in healthy individuals was 6.1% [seven participant]. The most frequent type was HPV-18 in five of them.HPV-6 and HPV-66 each was detected in one case. Relation of oral HPV positivity to demographic features and risk factors was not statistically significant. The prevalence of oral HPV infection in our community is the same as many other communities of developing countries, stressing that HPV-18 were the dominant type